A journey from research to entrepreneurship

Monday, December 03rd 2018

Okinawa Institute of Science and Technology

17:00 – 21:00 (JST)

Okinawa Institute of Science and Technology

View map

Do you want to attend? Get your ticket!

Register Now

Description

Being a relatively new university (since 2011), OIST promotes entrepreneurship to advance high-growth venture creation in Okinawa, working with government, academia, and industry on a shared vision and strategy for R&D cluster development.


Okinawa Protein Tomography (OPT) is OIST’s first successful startup company, that offer single molecule imaging at the remarkable resolution of 1.5 nanomters, which steadily improves. Established on June 25, 2014, by Prof. Ulf Skoglund, OPT is successfully managed by Mr. Akira Kamei since then and accumulated 80 M JPY capital. Mr Kamei will be able to share his personal experience on how is it to pioneer in a start-up ecosystem.


Please join us!

Speakers

Lukasz is a scientist with a strong focus on research applicability. He would like to help the most brilliant inventions to change the world as soon as possible!

During his student times, Lukasz was one of the founders of Oxbridge Biotech Roundtable, where he helped with organizing events and consulting projects. It was then where he developed passion for grassroot organizations, which eventually led him to Innovation Forum.
His research career started at University of Edinburgh with a BSc in Biotechnology followed by a PhD in Biotechnology at Cambridge, UK. His biological experience oscillates around synthetic biology, omics studies and clean power generation.

His previous leadership projects include proof-of-concept work with biofuel distillery waste and a scientific expedition to lake Baikal, Siberia.

Okinawa Protein Tomography provides macromolecular imaging service, that includes proteins in various states at the single molecule-level by combining conventional electron tomography and a specifically designed 3D reconstruction program known as COMET. The current resolution of a 3D image produced by this technique is approximately 1.5 nanometers and the resolution is steadily improving. For decades, pharmaceutical companies have studied the structure of proteins on the surface of human cells to develop drugs that latch onto the proteins and block the entry of a virus or bacteria. The new technology also allows visualization of protein complexes and their dynamics, serving as an alternative solution to the study of biological samples that are difficult or i... See more

Request sponsorship opportunities package

Sponsor this event
We use cookies to ensure that we give you the best tailored experience on our website based on your preferences. By continuing to use our services, you are giving us your consent to use cookies. Learn more here.